Skip to content

Study · Animal study (in vivo) · 2017

3 results

Altered sucrose self-administration following injection of melanocortin receptor agonists and antagonists into the ventral tegmental area.

Shanmugarajah L, Dunigan AI, Frantz KJ, Roseberry AG

Psychopharmacology27 Feb 2017Cited by 17 (Europe PMC)

PMID28243712 (opens in a new tab)DOI10.1007/s00213-017-4570-4 (opens in a new tab)PepBankPUB-28243712
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    Injection of MTII into the VTA decreased operant responding maintained by sucrose pellets on a fixed ratio schedule of reinforcement.

    In plain wordsIn animals, MTII injected into a brain area called the VTA reduced the effort made to earn sucrose pellets.

    Peptide
    Melanotan II
    Outcome
    DecreaseOperant responding for sucrose pellets, fixed ratio schedule
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · injection into the ventral tegmental areaAs given in this study.

    Source sentences

    Summary
    Injection of MTII into the VTA decreased operant responding maintained by sucrose pellets on both fixed ratio and progressive ratio schedules of reinforcement
    1 context sentence
    Summary · context
    We tested whether injection of the melanocortin receptor agonist, MTII, or the melanocortin receptor antagonist, SHU9119, directly into the VTA affected operant responding maintained by sucrose pellets in self-administration assays.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    Injection of MTII into the VTA decreased operant responding maintained by sucrose pellets on a progressive ratio schedule of reinforcement.

    In plain wordsIn animals, MTII injected into the VTA reduced how hard they worked to earn sucrose pellets.

    Peptide
    Melanotan II
    Outcome
    DecreaseOperant responding for sucrose pellets, progressive ratio schedule
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · injection into the ventral tegmental areaAs given in this study.

    Source sentences

    Summary
    Injection of MTII into the VTA decreased operant responding maintained by sucrose pellets on both fixed ratio and progressive ratio schedules of reinforcement
    1 context sentence
    Summary · context
    We tested whether injection of the melanocortin receptor agonist, MTII, or the melanocortin receptor antagonist, SHU9119, directly into the VTA affected operant responding maintained by sucrose pellets in self-administration assays.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    Injection of MTII into the VTA increased 24-h home-cage food intake.

    In plain wordsIn animals, MTII injected into the VTA raised food intake over 24 hours in the home cage.

    Peptide
    Melanotan II
    Outcome
    Increase24-h home-cage food intake
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    Dose not stated · injection into the ventral tegmental areaAs given in this study.

    Source sentences

    Summary
    MTII also increased and SHU9119 decreased 24-h home-cage food intake.
    1 context sentence
    Summary · context
    We tested whether injection of the melanocortin receptor agonist, MTII, or the melanocortin receptor antagonist, SHU9119, directly into the VTA affected operant responding maintained by sucrose pellets in self-administration assays.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.